Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. Issue 4 (October 2020)

• Record Type: Journal Article
• Authors: Majidi, Fatemeh; Martino, Samuela; Kondakci, Mustafa; Antke, Christina; Haase, Matthias; Chortis, Vasileios; Arlt, Wiebke; Ronchi, Cristina L; Fassnacht, Martin; Laurent, Claire; Petit, Jean-Michel; Casasnovas, Olivier; Habra, Amir Mouhammed; Kanji, Aleem; Salvatori, Roberto; Ho, An Thi Nhat; Spyroglou, Ariadni; Beuschlein, Felix; Villa, Diego; Limvorapitak, Wasithep; Wahlin, Björn Engelbrekt; Gimm, Oliver; Rudelius, Martina; Schott, Matthias; Germing, Ulrich; Haas, Rainer; Gattermann, Norbert
• Is Part Of: European journal of endocrinology. Volume 183:Issue 4(2020)
• Page Start: 453
• Page End: 462
• Publication Date: 2020-10
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EJE-19-0506
• Languages: English
• ISSNs: 0804-4643

Abstract

Abstract : Purpose: : We sought to refine the clinical picture of primary adrenal lymphoma (PAL), a rare lymphoid malignancy with predominant adrenal manifestation and risk of adrenal insufficiency. Methods: : Ninety-seven patients from 14 centers in Europe, Canada and the United States were included in this retrospective analysis between 1994 and 2017. Results: : Of the 81 patients with imaging data, 19 (23%) had isolated adrenal involvement (iPAL), while 62 (77%) had additional extra-adrenal involvement (PAL+). Among patients who had both CT and PET scans, 18FDG-PET revealed extra-adrenal involvement not detected by CT scan in 9/18 cases (50%). The most common clinical manifestations were B symptoms (55%), fatigue (45%), and abdominal pain (35%). Endocrinological assessment was often inadequate. With a median follow-up of 41.6 months, 3-year progression-free (PFS) and overall (OS) survival rates in the entire cohort were 35.5% and 39.4%, respectively. The hazard ratios of iPAL for PFS and OS were 40.1 (95% CI: 2.63–613.7, P = 0.008) and 2.69 (95% CI: 0.61–11.89, P = 0.191), respectively. PFS was much shorter in iPAL vs PAL+ (median 4 months vs not reached, P = 0.006), and OS also appeared to be shorter (median 16 months vs not reached), but the difference did not reach statistical significance ( P = 0.16). Isolated PAL was more frequent in females (OR = 3.81; P = 0.01) and less frequently associated with B symptoms (OR = 0.159; P = 0.004). Conclusion: : We found unexpected heterogeneity in the clinical spectrum of PAL. Further studies are needed to clarify whether clinical distinction between iPAL and PAL+ is corroborated by differences in molecular biology.